DAY ONE

DAY TWO

Day Two: Wednesday September 14, 2016

Past Agenda

REGISTRATION & COFFEE

8:00

Immunotherapy Round Up

8:30

Opening Remarks:

TBD

 

Roger Dansey

Senior Vice President Global Clinical Development Oncology

 

Merck

Biomarkers & Companion Diagnostics

9:00

Overview: Biomarkers and Companion Diagnostics in Anti PD-1 / Anti PDL-1 Immunotherapy

 

Arnold Gelb

Senior Director, Companion Diagnostics

 

EMD Serono

9:30


Plasma-Based Companion Diagnostics

 

Jean-Marie Bruey

Group Leader, Companion Diagnostics

 

Genentech

10:00

From bedside to bench, and back again: The clinical development of drug combination strategies in NSCLC

Adam Crystal

 

Clinical Program Leader

Novartis

PANEL DISCUSSION & SPEED NETWORKING

10:30

11:30

Plasma genotyping in Osimertinib (AZD9291) clinical trials; patient selection and mechanisms of resistance

 

Kenneth Thress

Oncology Translational Scientist

 

AstraZeneca

12:00

Path to Prospective Patient Selection in a Phase 2 Study of Seribantumab for Heregulin-Positive NSCLC

 

Art Kudla

Director, Clinical Development

 

Merrimack

12:30

Anti-Dll4 treatment in NCSLC: From preclinical to clinical

Fiore Cattaruzza

Senior Scientist - Translational Medicine,

 

 

Oncomed

LUNCH & NETWORKING

1:00

1:30

A pilot study to assess prognostic and predictive relevance of circulating tumor DNA and circulating tumor cells in patients with advanced small cell lung cancers.

 

Sunita Badola

Director, Functional Genomics

 

Takeda Oncology

2:00



Aejaz Nasir

Senior Medical Advisor & Surgical Pathology Lead

 

Eli Lilly

2:30

TARGETING CANCER STEM CELLS

Targeting FAK in the Tumor Microenvironment

 

David Weaver

Vice President, Head of Translational Research

 

Verastem

AFTERNOON REFRESHMENTS & NETWORKING

3:00

3:30


Targeting Tumor Recurrence Using Cancer Stem Cell Phenotypic Screens

Amy Hall

Senior Research Scientist

 

 

Vertex

4:00

Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients

 

Tim Heuer

Senior Director, Cell Biology

 

3-V Biosciences

4:30

Targeting RNA splicing in Lung Cancer

 

 

Peter Smith

Vice President, Drug Discovery

 

H3 Biomedicine

SUMMARY & CLOSE OF CONFERENCE

5:30

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2017 | All content produced by: neo-synth ltd.